Cardiac Failure Review最新文献

Myocardial Natriuretic Peptides and Oxygen Metabolism in Heart Failure. 心力衰竭时心肌利钠肽与氧代谢。

IF 5.7

Cardiac Failure Review Pub Date : 2026-03-31 eCollection Date: 2026-01-01 DOI: 10.15420/cfr.2025.58

Olli Arjamaa

{"title":"Myocardial Natriuretic Peptides and Oxygen Metabolism in Heart Failure.","authors":"Olli Arjamaa","doi":"10.15420/cfr.2025.58","DOIUrl":"10.15420/cfr.2025.58","url":null,"abstract":"Since the discovery of natriuretic peptides in the 1980s, initially as A-type natriuretic peptide, followed by B-type natriuretic peptide, their measurement has become standard in the management of heart failure (HF), as levels are markedly elevated in patients with HF. However, systematic reviews conducted in this area have yielded inconclusive results. Position and consensus papers on natriuretic peptides and HF have uniformly adopted the paradigm that myocardial stretch is the underlying mechanism explaining elevated circulating natriuretic peptide levels. Although mechanical stress is the primary factor determining myocardial oxygen consumption, this relationship has not been studied in HF. Biological evolution has developed a specific hypoxia-sensitive pathway in which a nuclear transcription factor, hypoxia-inducible factor, serves as the oxygen sensor, enabling myocardial cells to respond to reduced oxygen tension. In myocardial cell cultures, hypoxia was found to be a direct and sufficient stimulus for the expression of natriuretic peptides via the hypoxia-inducible factor pathway. Myocardial oxygen metabolism, which regulates plasma natriuretic peptide levels, presents a new objective for clinical research in HF.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"12 ","pages":"e06"},"PeriodicalIF":5.7,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13084723/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147724022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heart Failure in Hypertrophic Cardiomyopathy. 肥厚性心肌病的心力衰竭。

IF 5.7

Cardiac Failure Review Pub Date : 2026-03-02 eCollection Date: 2026-01-01 DOI: 10.15420/cfr.2025.25

Olives Nguyen, Daniel Kamna, Ahmad Masri

{"title":"Heart Failure in Hypertrophic Cardiomyopathy.","authors":"Olives Nguyen, Daniel Kamna, Ahmad Masri","doi":"10.15420/cfr.2025.25","DOIUrl":"https://doi.org/10.15420/cfr.2025.25","url":null,"abstract":"End-stage hypertrophic cardiomyopathy (ES-HCM) presents on a spectrum between the classic left ventricular systolic dysfunction and a less-recognised, restrictive phenotype with small-to-normal-sized left ventricular cavity and preserved ejection fraction. Relatively poor prognoses follow those on this morpho-functional spectrum, marked by low cardiac output and high arrhythmic risk. Contemporary guideline-directed therapies, such as ICDs, CRT and cardiac transplantation, have significantly improved outcomes, reshaping the natural history of ES-HCM. Meanwhile, the roles of neurohormonal modulation and left ventricular assist devices remain less well defined. Still, timely recognition and intervention remain essential in patients with ES-HCM, given its considerable morbidity and mortality. As cardiac myosin inhibitors and anti-fibrotic strategies advance, early targeted treatment may modify the natural history of hypertrophic cardiomyopathy, leading to a reduction in the incidence of ES-HCM. Moving forward, broader adoption of phenotype-specific approaches and equitable application of advanced therapies are critical to address the rare but clinically significant burden of ES-HCM.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"12 ","pages":"e05"},"PeriodicalIF":5.7,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12983141/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147469548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genetics in Hypertrophic Cardiomyopathy: An Evolving Clinical Landscape. 肥厚性心肌病的遗传学：一个不断发展的临床景观。

IF 5.7

Cardiac Failure Review Pub Date : 2026-02-19 eCollection Date: 2026-01-01 DOI: 10.15420/cfr.2025.12

María Noël Brögger, Ivonne Johana Cárdenas Reyes, Soledad García Hernández, Juan Pablo Ochoa

{"title":"Genetics in Hypertrophic Cardiomyopathy: An Evolving Clinical Landscape.","authors":"María Noël Brögger, Ivonne Johana Cárdenas Reyes, Soledad García Hernández, Juan Pablo Ochoa","doi":"10.15420/cfr.2025.12","DOIUrl":"https://doi.org/10.15420/cfr.2025.12","url":null,"abstract":"Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease and is characterised by unexplained increased wall thickness. Traditionally considered a monogenic disorder, emerging evidence highlights its complex genetic architecture. Genetic testing is now a cornerstone for diagnosis and family screening, although its prognostic and therapeutic impact at the individual level remains limited at present but is expected to grow as more comprehensive approaches are developed. Aimed at general cardiologists, this review summarises the benefits and limitations of current knowledge and genetic testing in HCM, and offers practical guidance on patient selection, interpretation of results, and integration into routine care. In this context, the challenge posed by variants of uncertain significance is discussed, and current and emerging strategies for their re-interpretation are outlined in brief. An updated overview is also provided of the genetic landscape, covering sarcomeric and non-sarcomeric genes, HCM phenocopies and new inheritance models, including oligogenic and polygenic mechanisms. Additionally, the potential of expanded genetic panels incorporating novel candidate genes and deep intronic and structural variants is highlighted. As gene therapy emerges as a future therapeutic option, precise molecular diagnosis will be essential for integrating genetic insights into routine clinical practice and advancing personalised care in HCM.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"12 ","pages":"e04"},"PeriodicalIF":5.7,"publicationDate":"2026-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12983145/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147469534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Apelin/APJ Signalling as a Potential Complementary Target for Glucagon-like Peptide-1 Receptor Agonist Therapy in Heart Failure. Apelin/APJ信号作为胰高血糖素样肽-1受体激动剂治疗心力衰竭的潜在补充靶点。

IF 5.7

Cardiac Failure Review Pub Date : 2026-02-19 eCollection Date: 2026-01-01 DOI: 10.15420/cfr.2025.54

Dominic Marcel Alfonso

引用次数: 0

Advances in Congestion Assessment in Decompensated Heart Failure. 失代偿性心力衰竭的充血评估进展。

IF 5.7

Cardiac Failure Review Pub Date : 2026-02-16 eCollection Date: 2026-01-01 DOI: 10.15420/cfr.2025.52

Archana Ganapathy, Jason N Dungu, Anthony D Dimarco, Andrew Madu, Brian Li, Samantha Langley, Peter Watters, Henry Oluwasefunmi Savage

引用次数: 0

The Role of Glucagon-like Peptide-1 in the Pathophysiology of Heart Failure: A Special Focus. 胰高血糖素样肽-1在心力衰竭病理生理中的作用：一个特别的焦点。

IF 5.7

Cardiac Failure Review Pub Date : 2026-02-06 eCollection Date: 2026-01-01 DOI: 10.15420/cfr.2025.55

Amina Rakisheva, Anton Zatsarinnyy

引用次数: 0

The Art and Science of Congestion Diagnosis and Management in Heart Failure. 心力衰竭充血诊断与处理的艺术与科学。

IF 5.7

Cardiac Failure Review Pub Date : 2025-12-23 eCollection Date: 2025-01-01 DOI: 10.15420/cfr.2025.53

Josip Andelo Borovac, Dino Miric

引用次数: 0

Phrenic Nerve Stimulation for Central Sleep Apnoea: When and Why? 膈神经刺激治疗中枢性睡眠呼吸暂停：何时及为何？

IF 5.7

Cardiac Failure Review Pub Date : 2025-12-19 eCollection Date: 2025-01-01 DOI: 10.15420/cfr.2025.32

Jonathan Na, Miguel Valderrabano, Paul Schurmann

引用次数: 0

Reverse Remodelling, Myocardial Recovery and Remission in Heart Failure with Reduced Ejection Fraction: Clinical Implications and Management Strategies. 心力衰竭伴射血分数降低的反向重构、心肌恢复和缓解：临床意义和管理策略。

IF 5.7

Cardiac Failure Review Pub Date : 2025-12-15 eCollection Date: 2025-01-01 DOI: 10.15420/cfr.2025.41

Silas Ramos Furquim, Maria Tereza Sampaio de Sousa Lira, Deborah de Sá Pereira Belfort, Bruno Biselli, Paulo Roberto Chizzola, Robinson Tadeu Munhoz, Edimar Alcides Bocchi, Silvia Moreira Ayub-Ferreira

{"title":"Reverse Remodelling, Myocardial Recovery and Remission in Heart Failure with Reduced Ejection Fraction: Clinical Implications and Management Strategies.","authors":"Silas Ramos Furquim, Maria Tereza Sampaio de Sousa Lira, Deborah de Sá Pereira Belfort, Bruno Biselli, Paulo Roberto Chizzola, Robinson Tadeu Munhoz, Edimar Alcides Bocchi, Silvia Moreira Ayub-Ferreira","doi":"10.15420/cfr.2025.41","DOIUrl":"10.15420/cfr.2025.41","url":null,"abstract":"Cardiac reverse remodelling (RR) is a complex process involving structural and functional recovery of the myocardium, with significant implications for the prognosis of patients with heart failure (HF). This review summarises current concepts, underlying mechanisms, therapeutic strategies, and clinical implications of RR, while distinguishing it from myocardial recovery and remission. Both pharmacological therapies and non-pharmacological interventions have shown potential to induce RR in selected populations. Clinical features, echocardiographic parameters, advanced imaging findings, and biomarkers help stratify patients according to the likelihood of recovery and risk of relapse. The management of HF with improved ejection fraction remains debated. High recurrence rates are seen after therapy discontinuation; however, evidence suggests that partial withdrawal may be safe in specific patient profiles. RR should be considered a central therapeutic goal in HF care, although its extent and stability vary widely. Differentiating between transient improvement, remission under therapy, and true myocardial recovery is critical for guiding long-term treatment decisions, highlighting the importance of individualised follow-up.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"11 ","pages":"e33"},"PeriodicalIF":5.7,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12784276/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145953060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ventricular-Arterial Coupling in Heart Failure with Preserved Ejection Fraction: A Bibliometric Review and Clinical Implications. 保留射血分数的心力衰竭的心室-动脉耦合：文献计量学回顾和临床意义。

IF 5.7

Cardiac Failure Review Pub Date : 2025-12-04 eCollection Date: 2025-01-01 DOI: 10.15420/cfr.2025.27

Tianzong Li, Yiran Luo, Lina Zhao, Fangfang Lu, Bei Zhang

{"title":"Ventricular-Arterial Coupling in Heart Failure with Preserved Ejection Fraction: A Bibliometric Review and Clinical Implications.","authors":"Tianzong Li, Yiran Luo, Lina Zhao, Fangfang Lu, Bei Zhang","doi":"10.15420/cfr.2025.27","DOIUrl":"10.15420/cfr.2025.27","url":null,"abstract":"Heart failure remains a growing global health burden, and early disruptions in ventricular-arterial coupling (VAC) contribute to its pathogenesis, particularly in heart failure with preserved ejection fraction (HFpEF). We conducted an integrative bibliometric and thematic review of Web of Science records (search on 1 March 2025; coverage through December 2024) to map how VAC has evolved from a mechanistic construct to a clinically actionable framework in HFpEF. Output accelerated since 2006, with four core clusters spanning haemodynamics, right ventricle- pulmonary artery coupling, arterial stiffness, and clinical imaging. VAC has steadily moved physiological constructs toward clinical risk stratification, especially in HFpEF and right ventricular dysfunction. Important gaps include non-standardised assessment and limited prospective validation of VAC-targeted interventions. This review synthesises mechanistic and clinical evidence across the left atrial, left ventricular, and right ventricle-pulmonary artery axes and, on that basis, sets practical priorities for measurement standardisation and prospective validation within a whole-heart perspective.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"11 ","pages":"e32"},"PeriodicalIF":5.7,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12723819/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145828481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0